Anthony Giovinazzo, a Director, acquired 325,000 Common Shares on a direct ownership basis at a price of $0.230 through a prospectus or prospectus exempt offering on January 22nd, 2019. The insider also acquired 325,000 Warrants with an exercise price of $0.480 for five long years. This represents a $74,750 investment into the company's shares and an account share holdings change of 38.2%.
Elliot Paul Goldstein, CEO and Director, acquired 115,607 Common Shares and 115,607 Warrants on a direct ownership basis. This represents a $26,590 investment into the company's shares and an account share holdings change of 1.6%.
Eugene Warren Williams, a Director, acquired 115,607 Common Shares and 115,607 Warrants on a direct ownership basis. This represents a $26,590 investment into the company's shares and an account share holdings change of 1.5%.
ProMIS Neurosciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
No Comments